1620 Investment Advisors, Inc. Neurocrine Biosciences Inc Transaction History
1620 Investment Advisors, Inc.
- $125 Million
- Q1 2025
A detailed history of 1620 Investment Advisors, Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, 1620 Investment Advisors, Inc. holds 927 shares of NBIX stock, worth $115,875. This represents 0.08% of its overall portfolio holdings.
Number of Shares
927
Previous 933
0.64%
Holding current value
$115,875
Previous $127,000
19.69%
% of portfolio
0.08%
Previous 0.1%
Shares
4 transactions
Others Institutions Holding NBIX
# of Institutions
649Shares Held
97.1MCall Options Held
749KPut Options Held
553K-
Black Rock Inc. New York, NY14.2MShares$1.77 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.94MShares$1.24 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.53MShares$692 Million0.37% of portfolio
-
State Street Corp Boston, MA4.86MShares$608 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY2.67MShares$334 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $12B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...